Not yet recruitingPhase IIInterventional

Deferred registration - AstraZeneca/United Kingdom Code: D7260C00014

This is a Phase II clinical study sponsored by AstraZeneca in the United Kingdom. It is designed for infants aged between zero and one year. At present, specific information regarding the medical condition being treated, the study medication, and the testing procedures has not yet been released publicly. In the UK, the Health Research Authority (HRA) can grant a temporary delay, known as a deferred registration. This is a standard process that protects sensitive scientific or commercial information for a short time before a study opens widely. Even though the details are currently withheld from public view, the trial must still meet all strict UK safety, ethical, and regulatory standards. The full scientific details and study requirements will be published on the official trial registry on or before the agreed expiry date.

At a glance

Status

Not yet recruiting

Phase

Phase II

Sponsor

AstraZeneca (Sweden)

Enrolment target

100

Start

03 May 2027

Estimated completion

02 Nov 2028

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

What is this study about?

This clinical trial, known by the reference code D7260C00014, is being conducted in the UK by the pharmaceutical company AstraZeneca. It is a Phase II trial, which means researchers are looking to see how well a treatment works and to check for any side effects in a specific group of people. What makes this study unique on the public registry right now is that its full details are temporarily kept private.

In the UK, health research is carefully monitored by the Health Research Authority (HRA). Sometimes, researchers ask the HRA for permission to delay publishing the full description of a study. This is called a deferred registration. The HRA only approves this when there is a good reason, such as safeguarding scientific research plans or commercial details. Crucially, a deferral does not mean safety rules have been skipped. The study has still undergone rigorous ethical review to ensure that taking part is as safe as possible.

We do know that this study involves babies aged up to one year old. Paediatric research like this is vital because medicines must be carefully tested in children, rather than doctors simply guessing doses based on adult data. Once the approved deferral date arrives, AstraZeneca will update the registry with full information about the condition being treated and how the study is run.

Key takeaways

This is a Phase II clinical trial sponsored by AstraZeneca in the UK.
The study is designed for infants aged between 0 and 1 year.
Detailed study information is temporarily delayed with approval from the UK Health Research Authority (HRA).
All standard UK ethical and safety reviews still apply to this study.
Complete details about the condition, treatment, and visits will be published once the deferral expires.

Who may be eligible?

Because this study is under a temporary publication delay, the exact medical checklist for who can and cannot join is not yet available to the public.

However, the trial listing confirms that it is open to both boys and girls who are infants between birth and one year of age. There will be specific medical requirements that doctors use to decide if a child is suitable.

Once the Health Research Authority deferral expires, a complete list of inclusion and exclusion criteria will be posted on the public registry.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Your child is an infant aged between 0 and 12 months.
You are interested in learning about new clinical studies for babies in the UK.
You are willing to wait for full medical details to be published on the registry.
You are prepared to discuss clinical trials with your child's paediatrician or GP.

Answer every question to see your result.

What does participation involve?

At this stage, specific details about what taking part involves have not been published. Generally, Phase II trials in young children involve close monitoring by a specialist medical team. This typically includes regular check-ups, health assessments, and carefully measured doses of a medicine. The exact number of hospital visits, how the treatment is given, and how long the study will last will be shared when the full trial details are released.

Potential risks and benefits

Any clinical trial involves potential benefits and risks. The potential benefit may be receiving close expert care and helping to develop new treatments for young children. Potential risks can include unexpected side effects from a new medication or the discomfort of medical checks. Because this study involves infants, UK ethics committees apply exceptionally strict safety standards. Joining a trial is always completely voluntary. Parents or guardians can withdraw their child from a study at any time without giving a reason and without it affecting their normal NHS care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.
City only
Oxford, England

Common questions

Why are the study details hidden?

The UK Health Research Authority (HRA) granted a temporary deferral to protect sensitive research information. The full details will be published once this period ends.

Is a deferred clinical trial safe?

Yes. A deferred trial must still pass the same strict UK safety and ethical checks as any other clinical trial before it can treat patients.

Who can take part in this trial?

The only confirmed detail right now is that it is for infants from birth up to one year old. Specific medical criteria will be published later.

Do I have to pay for my baby to take part in a UK clinical trial?

No. In the UK, treatments and tests carried out as part of an approved clinical trial are free of charge, and travel expenses are often covered.

Can I withdraw my child from the study later?

Yes. You have the legal right to stop taking part at any time. Doing so will never harm or change the everyday NHS care your child receives.

How to find out more

Marleen Roels

marleen.roels@astrazeneca.com 46720140219 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.